Docoh
Loading...

ICAD Icad

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment include image analysis and workflow products. The Cancer Therapy segment consists radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Company profile

Ticker
ICAD
Exchange
Website
CEO
Michael S. Klein
Employees
Incorporated
Location
Fiscal year end
Former names
HOWTEK INC
SEC CIK
IRS number
20377419

ICAD stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Mar 21
21 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Icad earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 27.19M 27.19M 27.19M 27.19M 27.19M 27.19M
Cash burn (monthly) (positive/no burn) (positive/no burn) 533K 1.46M 300.67K 582.08K
Cash used (since last report) n/a n/a 1.97M 5.42M 1.11M 2.15M
Cash remaining n/a n/a 25.21M 21.77M 26.07M 25.03M
Runway (months of cash) n/a n/a 47.3 14.9 86.7 43.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Feb 21 Klein Michael S Stock Option Common Stock Grant Aquire A No No 18 76,982 1.39M 76,982
15 Feb 21 Go Jonathan Stock Option Common Stock Grant Aquire A No No 18 24,286 437.15K 24,286
15 Feb 21 Areglado R. Scott Stock Option Common Stock Grant Aquire A No No 18 23,689 426.4K 23,689
15 Feb 21 Stevens Stacey M Stock Option Common Stock Grant Aquire A No No 18 33,981 611.66K 33,981
15 Feb 21 Sassine Andy Common Stock Grant Aquire A No No 0 3,500 0 1,318,382
15 Feb 21 Sassine Andy Stock Option Common Stock Grant Aquire A No No 18 30,000 540K 30,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

43.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 81 79 +2.5%
Opened positions 8 11 -27.3%
Closed positions 6 17 -64.7%
Increased positions 29 30 -3.3%
Reduced positions 35 24 +45.8%
13F shares
Current Prev Q Change
Total value 664.35M 135.33M +390.9%
Total shares 10.77M 9.93M +8.5%
Total puts 0 16.3K EXIT
Total calls 85.5K 85.4K +0.1%
Total put/call ratio 0.2
Largest owners
Shares Value Change
BLK Blackrock 1.45M $19.17M +3.1%
Portolan Capital Management 1.16M $15.33M +138.0%
Vanguard 1.07M $14.18M +1.2%
G2 Investment Partners Management 885.37K $11.69M -20.0%
FHI Federated Hermes 649.55K $8.57M 0.0%
Parkman Healthcare Partners 542.6K $7.16M -6.7%
Wellington Management 456.7K $6.03M +48.6%
STT State Street 336.13K $4.44M +13.2%
Geode Capital Management 311.12K $4.11M +3.3%
Renaissance Technologies 260.59K $3.44M -31.7%
Largest transactions
Shares Bought/sold Change
Portolan Capital Management 1.16M +673.28K +138.0%
Schonfeld Strategic Advisors 110.7K -227.3K -67.2%
G2 Investment Partners Management 885.37K -221.01K -20.0%
DB Deutsche Bank AG - Registered Shares 192.63K +181.38K +1611.5%
Granite Point Capital Management 178.57K +178.57K NEW
Wellington Management 456.7K +149.3K +48.6%
Renaissance Technologies 260.59K -120.98K -31.7%
Essex Investment Management 113.4K +113.4K NEW
Russell Investments 260.21K +103.82K +66.4%
Millrace Asset 45.97K -95.43K -67.5%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Alliance, alter, ATM, Bangladesh, benchmark, Biden, brokerage, cancelling, capacity, carefully, deduced, detector, distancing, dosage, dosimetric, duration, ease, Edition, encouraging, Ewing, feasible, felt, flat, foremost, fuller, Germany, gradual, Guggenheim, hosting, incentivizing, inline, Institutet, Interbank, issuedASU, JMP, Kesari, lender, LIBOR, makea, motivate, nationwide, nearby, noncompliance, notice, onset, outpatient, pandemic, partly, printed, prompted, radiochromic, referenced, requisite, resurgence, reward, risky, RO, Santosh, scalability, social, stone, stream, succeed, supposed, SVB, switch, Therapixel, tied, transformation, unaccrued, underwent, unprecedented, vacation, vivo, waiver, Wall, worsening, wrote
Removed: accrual, accrue, Acorn, acumen, adherence, age, agent, Andy, anniversary, annum, assetor, attachment, Bachelor, back, BESP, biopharma, Bird, borrow, borrowed, burn, CADx, caption, chair, charter, Christopher, Clarke, collectability, commitment, concluding, confidence, consistency, constituted, CRA, deficiency, deliverable, description, determinable, discontinuance, discontinue, dissolved, division, Dr, drawn, driver, earliest, EBITDA, effected, escrow, ethical, ExBRT, exceeding, excise, excluding, existed, expert, expertise, Fidelity, Fleet, floating, focusing, forfeiture, franchise, Freedom, gain, Gemphire, Harvard, Hearing, honesty, indefinite, Insider, Iowa, Jeffrey, joining, Kenneth, knowledge, leader, led, liable, manager, mature, MBA, Meditech, Mexico, modifying, MYnd, ninety, Nominating, noted, objective, occasion, occupation, Pennsylvania, persuasive, plea, postponement, president, pursue, Ratification, registration, Revolution, safely, Sassine, Science, Secretary, server, sound, Speech, subsidize, superseded, surrendered, suspended, taxing, Tippie, TPE, trailing, twelve, ultrasound, unaudited, upcoming, vice, VSOE, Wharton, woman, writing, XAC